What's Happening?
ImmunityBio, a commercial-stage immunotherapy company, has signed an exclusive U.S. agreement with Japan BCG Laboratory for the Tokyo strain of BCG. This agreement aims to enhance the supply of BCG in the United
States, addressing a long-standing shortage. The Tokyo strain has shown non-inferior efficacy compared to TICE BCG in treating high-grade non-muscle invasive bladder cancer. ImmunityBio will be the sole U.S. Biologics License Application applicant and plans to engage with the FDA to pursue approval. The agreement provides a second potential BCG source for the U.S., complementing ImmunityBio's partnership with the Serum Institute of India.
Why It's Important?
The agreement is crucial in addressing the decade-long BCG shortage in the U.S., which has impacted treatment options for bladder cancer patients. By securing a reliable supply of the Tokyo strain, ImmunityBio can potentially improve patient outcomes and expand treatment options. The partnership with Japan BCG Laboratory and the Serum Institute of India positions ImmunityBio as a key player in the U.S. BCG market. This development also highlights the importance of international collaborations in overcoming supply chain challenges in the healthcare sector.
What's Next?
ImmunityBio plans to engage with the FDA to discuss the regulatory pathway for the Tokyo strain of BCG. The company will lead all regulatory submissions and commercialization efforts in the U.S. ImmunityBio's ongoing partnership with the Serum Institute of India will continue to support the supply of recombinant BCG under the FDA's Expanded Access Program. The company is expected to provide further updates on the regulatory process and potential market entry timelines.
